Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma.
Murtuza BharmalSandra NolteMickaël Henry-SzatkowskiMeliessa HennessyMichael SchlichtingPublished in: Health and quality of life outcomes (2020)
This study is a pre-planned post-hoc analysis conducted on data collected in Part A and Part B of the JAVELIN Merkel 200 trial. This trial was registered on 2 June 2014 with ClinicalTrials.gov as NCT02155647.